Home » Healthcare » Pharmaceuticals » Alzheimer’s Therapeutic Market

Alzheimer’s Therapeutic Market By Drug Name (Donepezil, Rivastigmine, Memantine, Galantamine, Manufactured Combination of Memantine and Donepezil) By Drug Class (Cholinesterase Inhibitors, NMDA Receptor Antagonists, Manufactured Combination) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies) – Growth, Share, Opportunities & Competitive Analysis, 2016 – 2028

Summary
Table Of Content

How Rising Prevalence of Prevalence of Target Diseases and Increasing Geriatric Population Supported the Growth of Alzheimer’s Therapeutic Market?

The global Alzheimer’s therapeutics market is increasing considerably due to the increasing prevalence and incidence rates of this illness and the growing geriatric population base. The World Health Organization (WHO) estimates that 50 million people will have Alzheimer’s disease in 2021, with about 10 million new cases diagnosed yearly. It mainly affects adults over the age of 65. Additionally, it is anticipated that increased awareness of its symptoms, such as partial dementia, will increase demand. The total cost of Alzheimer’s disease is rising as more expensive medications, and treatments are used to manage the condition. The National Library of Medicine estimates that by 2030, the expense of Alzheimer’s disease to the world economy will rise from USD 818 billion to USD 2 trillion.

What is the Market Size of the Alzheimer’s Therapeutic Market in terms of value?

The global Alzheimer’s Therapeutic Market is projected to increase at a significant CAGR of 9.1% in the coming years. In 2021, the global Alzheimer’s Therapeutic market was valued at USD 2491.5 million and projected to reach USD 4201.54 million by 2028. The demand for Alzheimer’s Therapeutic is projected to increase substantially in the coming years. It is presumed to generate revenue opportunities for the key industry players worth USD 1710.04 million over the forecast period between 2022 and 2028.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

How Technological Advancements for the Development of Innovative Drugs Play an Important Role in Alzheimer’s Therapeutic Market?

Growing investment in R&D activities and technical developments for the creation of innovative medications and techniques for the treatment of Alzheimer’s disease are contributing to the market expansion of the Alzheimer’s Therapeutic market. The sale of Alzheimer’s treatments is increasing due to the increased use of generic pharmaceuticals such as Donepezil by people and the greater use of biomarkers in Alzheimer’s diagnosis and therapy research. Numerous studies are being conducted worldwide to develop diagnostic tools for treating Alzheimer’s. New technologies are helpful in the diagnosis and treatment of Alzheimer’s disease in addition to conventional therapeutic approaches. The global market for therapeutics for Alzheimer’s disease is expected to grow over the forecast period due to rising healthcare awareness and better diagnostic tools for the condition. The National Institute on Aging reports that more than 25 new genes are implicated in Alzheimer’s disease and are important in its management. Researchers are identifying potential targets for medications and non-drug therapies to treat or stop the disease by figuring out these pathways.

Interesting Facts about Alzheimer’s Therapeutic Industry

Alzheimer’s is a form of dementia that affects the patient’s behavior, thinking, and memory. The disease is steadily progressing, but the neurons in the area of the brain responsible for learning are deteriorating. It is the most prevalent type of dementia in adults over 65.
The increased incidence and prevalence of Alzheimer’s disease, expanding public health awareness about the condition, and the development of breakthrough technologies and treatments to extend life expectancy are all driving significant growth in the market.
Late-stage medication failures, an absence of surrogate markers for drug discovery and development, insufficient research funding, and lengthy unclear processes are projected to hinder growth in the global Alzheimer’s Therapeutic market during the forecast period.
The North American region had a major share in volume and value in the global Alzheimer’s Therapeutic market in 2021 and is projected to continue its dominance over the forecast period.
Cholinesterase Inhibitors segment to witness high growth during the forecast period as they are frequently utilized by healthcare practitioners to address disorders linked to memory, thinking, language, judgment, and other thought processes.

Who are the Top 10 players/companies in the Alzheimer’s Therapeutic market regarding value and volume?

The key players in the global Alzheimer’s Therapeutic market in terms of value and volume include AbbVie Inc., Lannett Inc., Teva Pharmaceuticals Ltd, Unichem laboratories Ltd, Eisai Co. Ltd, Torrent Pharmaceuticals Ltd, Janssen Pharmaceuticals Inc. (Johnson & Johnson), Cipla Ltd, Novartis Novartis AG, Lupin Ltd, Zydus Lifesciences Ltd (CADILA), Viatris Inc, Sun Pharmaceutical Industries Ltd, Macleods Pharmaceuticals Ltd, Dr. Reddy’s Laboratories Ltd, Aurobindo Pharma Ltd, and Amneal Pharmaceuticals Inc. These key players are concentrating on new product developments as well as technological innovation to enhance their production of Alzheimer’s Therapeutics to gain competitive market share at a global level. For instance, in March 2022, Biogen Inc. and Eisai Co. Ltd. expanded their existing partnership deal for Alzheimer’s disease treatments. On the other hand, in November 2021, Brigham and Women’s Hospital in Boston, Massachusetts, began a clinical trial to evaluate the safety and efficacy of a new nasal vaccine for Alzheimer’s disease.

Who are the Top 10 Countries in the Alzheimer’s Therapeutic Market?

In the global Alzheimer’s Therapeutic market, the major countries are China, India, the U.S., Canada, the U.K., Germany, France, Russia, Switzerland, Japan, and Australia. The U.S. is the most profitable market for Alzheimer’s therapeutics due to the region’s increasing prevalence of Alzheimer’s disease and other types of dementia, significant investment in research and development activities and the launch of new products. Also, China holds 41.2% of the East Asian market for Alzheimer’s Therapeutic market as of 2021, owing to the country’s fast-developing medical infrastructure, an increase in scientific research into the diagnosis, treatment, and monitoring of the disease, as well as significant investment from both the public and commercial sectors for Alzheimer’s research.

Which is the Key Application Area in the Alzheimer’s Therapeutic Market?

The cholinesterase inhibitors segment has the highest revenue share of the global Alzheimer’s Therapeutics market in 2021. It is expected to dominate the market over the forecast period since they are commonly used by healthcare professionals to treat symptoms associated with memory, thinking, language, judgment, and other thought processes. This is propelling the market.

In addition, in Alzheimer’s disease, there has been a rise in the applications of various machine learning approaches, most commonly with imaging data, for diagnosis and disease progression. This includes, among other things, amyloid PET imaging, combined PET and MR imaging, and spectral phenotyping. For instance, researchers from the VA healthcare systems in Bedford and Boston created a non-invasive optical technique that aids in the diagnosis of Alzheimer’s disease. This novel method employs spectroscopy to detect structural changes in the brain. This technological advancement has evolved to meet the needs of people living with dementia, informal caregivers, formal caregivers, and social caregivers, creating a massive opportunity in the Alzheimer’s therapeutics market.

What are the Major Driving Factors for Alzheimer’s Therapeutic Market?

The Global Alzheimer’s Therapeutic Market is predicted to experience exceptional growth over the forecast years attributable to the increasing demand for minimally invasive procedures in treating Alzheimer’s illness. The rising incidence and prevalence of Alzheimer’s disease, rising public health awareness about the disease, and the introduction of novel technologies and drugs to improve life expectancy are all driving significant growth in the Global Alzheimer’s Therapeutic market. Growing investment in R&D activities and technological developments to create novel drugs and methods for treating Alzheimer’s disease contribute to market growth. Moreover, the global aging population, growth in the healthcare sector, and increased government initiatives and support in the form of funds and grants to enhance diagnostic techniques and treatment procedures all contribute to the growth of the Alzheimer’s Therapeutic market.

What are the Major Restraints for Alzheimer’s Therapeutic Market?

Late-stage drug failures, an absence of surrogate markers for drug discovery and development, inadequate research funding, and lengthy uncertain processes are expected to suppress growth in the global Alzheimer’s Therapeutic market throughout the forecast period. Many Alzheimer’s therapies, including donepezil and others, have been phased out recently. According to the National Library of Medicine, donepezil was discontinued in 2021 due to adverse effects on patients, which was the primary reason for its discontinuation. Moreover, the shortage of skilled medical professionals, combined with an unfavorable reimbursement scenario in developing and underdeveloped economies, will pose a significant challenge to market growth.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Which Region Dominated the World Alzheimer’s, Therapeutic Market?

In 2021, North America will have the highest revenue share in the Global Alzheimer’s Therapeutic Market and is expected to maintain its dominance throughout the forecast period. The increased spending in R&D activities for developing technologically advanced techniques and innovative drugs to treat Alzheimer’s disease is primarily responsible for revenue growth in the North American market. Moreover, the region’s growing geriatric population, rising incidence and prevalence of Alzheimer’s disease, expanding healthcare sectors, presence of skilled professionals, and widespread availability of technologically advanced Alzheimer’s Therapeutic are major factors driving the Alzheimer’s Therapeutic market. For instance, the Journal of the Alzheimer’s Association reports that 10.7% of Americans 65 and older, or about 1 in 9 people, in the United States have Alzheimer’s dementia. Alzheimer’s dementia affects approximately 5% aged 65-74, 13.1% of the population aged 75-84, and 33.2% aged 85 and older.

However, the Asia Pacific market is also expected to expand at a significant rate during the forecast period, owing to an increased focus on the development of healthcare infrastructure and the rising prevalence of Alzheimer’s disease in developing countries such as China and India in this region.

Segmentation of Global Alzheimer’s Therapeutic Market –

Global Alzheimer’s Therapeutic Market – By Drug Name

Donepezil
Rivastigmine
Memantine
Galantamine
Manufactured Combination of Memantine and Donepezil

Global Alzheimer’s Therapeutic Market – By Drug Class

Cholinesterase Inhibitors
NMDA Receptor Antagonists
Manufactured Combination

Global Alzheimer’s Therapeutic Market – By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Approach Adopted
1.3.4.1. Top-Down Approach
1.3.4.2. Bottom-Up Approach
1.3.5. Assumptions
1.4. Market Segmentation

2. Executive Summary
2.1. Market Snapshot: Global Alzheimer’s Therapeutic Market

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Alzheimer’s Therapeutic Market Value, 2016-2028, (US$ Bn)
3.2. Market Dynamics
3.2.1. Key Growth Trends
3.2.2. Major Industry Challenges
3.2.3. Key Growth Pockets
3.3. Attractive Investment Proposition,2021
3.3.1. Drug Class
3.3.2. Distribution Channels
3.3.3. Treatment
3.4. Porter’s Five Forces Analysis
3.4.1. Threat of New Entrants
3.4.2. Bargaining Power of Buyers/Consumers
3.4.3. Bargaining Power of Suppliers
3.4.4. Threat of Substitute Types
3.4.5. Intensity of Competitive Rivalry
3.5. Value Chain Analysis

4. Market Positioning of Key Players, 2021
4.1. Company market share of key players, 2021
4.2. Top 6 Players
4.3. Top 3 Players
4.4. Major Strategies Adopted by Key Players

5. COVID 19 Impact Analysis
5.1. Global Alzheimer’s Therapeutic Market Pre Vs Post COVID 19, 2019 – 2028
5.2. Impact on Import & Export
5.3. Impact on Demand & Supply

6. North America
6.1. North America Alzheimer’s Therapeutic Market, by Country, 2016-2028(US$ Bn)
6.1.1. U.S.
6.1.2. Canada
6.1.3. Mexico
6.2. North America Alzheimer’s Therapeutic Market, by Drug Class, 2016-2028(US$ Bn)
6.2.1. Overview
6.2.2. Cholinesterase Inhibitors
6.2.3. NMDA Receptor Antagonists
6.2.4. Others
6.3. North America Alzheimer’s Therapeutic Market, by Distribution Channels, 2016-2028(US$ Bn)
6.3.1. Overview
6.3.2. Hospital Pharmacy
6.3.3. Retail Pharmacy
6.3.4. Online Pharmacy
6.3.5. Others
6.4. North America Alzheimer’s Therapeutic Market, by Treatment, 2016-2028(US$ Bn)
6.4.1. Overview
6.4.2. Donepezil
6.4.3. Rivastigmine
6.4.4. Memantine
6.4.5. Galantamine
6.4.6. Manufactured Combination of Memantine and Donepezil
6.4.7. Other

7. Europe
7.1. Europe Alzheimer’s Therapeutic Market, by Country, 2016-2028(US$ Bn)
7.1.1. UK
7.1.2. France
7.1.3. Germany
7.1.4. Italy
7.1.5. Russia
7.1.6. Ukraine
7.1.7. Spain
7.1.8. Belgium
7.1.9. Netherland
7.1.10. Austria
7.1.11. Sweden
7.1.12. Poland
7.1.13. Denmark
7.1.14. Switzerland
7.1.15. Rest of Europe
7.2. Europe Alzheimer’s Therapeutic Market, by Drug Class, 2016-2028(US$ Bn)
7.2.1. Overview
7.2.2. Cholinesterase Inhibitors
7.2.3. NMDA Receptor Antagonists
7.2.4. Others
7.3. Europe Alzheimer’s Therapeutic Market, by Distribution Channels, 2016-2028(US$ Bn)
7.3.1. Overview
7.3.2. Hospital Pharmacy
7.3.3. Retail Pharmacy
7.3.4. Online Pharmacy
7.3.5. Others
7.4. Europe Alzheimer’s Therapeutic Market, by Treatment, 2016-2028(US$ Bn)
7.4.1. Overview
7.4.2. Donepezil
7.4.3. Rivastigmine
7.4.4. Memantine
7.4.5. Galantamine
7.4.6. Manufactured Combination of Memantine and Donepezil
7.4.7. Other

8. Asia Pacific
8.1. Asia Pacific Alzheimer’s Therapeutic Market, by Country, 2016-2028(US$ Bn)
8.1.1. China
8.1.2. Japan
8.1.3. South Korea
8.1.4. India
8.1.5. Australia
8.1.6. New Zealand
8.1.7. Taiwan
8.1.8. Indonesia
8.1.9. Malaysia
8.1.10. Philippine
8.1.11. Rest of Asia Pacific
8.2. Asia Pacific Alzheimer’s Therapeutic Market, by Drug Class, 2016-2028(US$ Bn)
8.2.1. Overview
8.2.2. Cholinesterase Inhibitors
8.2.3. NMDA Receptor Antagonists
8.2.4. Others
8.3. Asia Pacific Alzheimer’s Therapeutic Market, by Distribution Channels, 2016-2028(US$ Bn)
8.3.1. Overview
8.3.2. Hospital Pharmacy
8.3.3. Retail Pharmacy
8.3.4. Online Pharmacy
8.3.5. Others
8.4. Asia Pacific Alzheimer’s Therapeutic Market, by Treatment, 2016-2028(US$ Bn)
8.4.1. Overview
8.4.2. Donepezil
8.4.3. Rivastigmine
8.4.4. Memantine
8.4.5. Galantamine
8.4.6. Manufactured Combination of Memantine and Donepezil
8.4.7. Other

9. Latin America
9.1. Latin America Alzheimer’s Therapeutic Market, by Country, 2016-2028(US$ Bn)
9.1.1. Brazil
9.1.2. Argentina
9.1.3. Peru
9.1.4. Chile
9.1.5. Colombia
9.1.6. Rest of Latin America
9.2. Latin America Alzheimer’s Therapeutic Market, by Drug Class, 2016-2028(US$ Bn)
9.2.1. Overview
9.2.2. Cholinesterase Inhibitors
9.2.3. NMDA Receptor Antagonists
9.2.4. Others
9.3. Latin America Alzheimer’s Therapeutic Market, by Distribution Channels, 2016-2028(US$ Bn)
9.3.1. Overview
9.3.2. Hospital Pharmacy
9.3.3. Retail Pharmacy
9.3.4. Online Pharmacy
9.3.5. Others
9.4. Latin America Alzheimer’s Therapeutic Market, by Treatment, 2016-2028(US$ Bn)
9.4.1. Overview
9.4.2. Donepezil
9.4.3. Rivastigmine
9.4.4. Memantine
9.4.5. Galantamine
9.4.6. Manufactured Combination of Memantine and Donepezil
9.4.7. Other

10. Middle East
10.1. Middle East Alzheimer’s Therapeutic Market, by Country, 2016-2028(US$ Bn)
10.1.1. UAE
10.1.2. KSA
10.1.3. Israel
10.1.4. Turkey
10.1.5. Iran
10.1.6. Rest of Middle East
10.2. Middle East Alzheimer’s Therapeutic Market, by Drug Class, 2016-2028(US$ Bn)
10.2.1. Overview
10.2.2. Cholinesterase Inhibitors
10.2.3. NMDA Receptor Antagonists
10.2.4. Others
10.3. Middle East Alzheimer’s Therapeutic Market, by Distribution Channels, 2016-2028(US$ Bn)
10.3.1. Overview
10.3.2. Hospital Pharmacy
10.3.3. Retail Pharmacy
10.3.4. Online Pharmacy
10.3.5. Others
10.4. Middle East Alzheimer’s Therapeutic Market, by Treatment, 2016-2028(US$ Bn)
10.4.1. Overview
10.4.2. Donepezil
10.4.3. Rivastigmine
10.4.4. Memantine
10.4.5. Galantamine
10.4.6. Manufactured Combination of Memantine and Donepezil
10.4.7. Other

11. Africa
11.1. Africa Alzheimer’s Therapeutic Market, by Country, 2016-2028(US$ Bn)
11.1.1. South Africa
11.1.2. Egypt
11.1.3. Nigeria
11.1.4. Rest of Africa
11.2. Africa Alzheimer’s Therapeutic Market, by Drug Class, 2016-2028(US$ Bn)
11.2.1. Overview
11.2.2. Cholinesterase Inhibitors
11.2.3. NMDA Receptor Antagonists
11.2.4. Others
11.3. Africa Alzheimer’s Therapeutic Market, by Distribution Channels, 2016-2028(US$ Bn)
11.3.1. Overview
11.3.2. Hospital Pharmacy
11.3.3. Retail Pharmacy
11.3.4. Online Pharmacy
11.3.5. Others
11.4. Africa Alzheimer’s Therapeutic Market, by Treatment, 2016-2028(US$ Bn)
11.4.1. Overview
11.4.2. Donepezil
11.4.3. Rivastigmine
11.4.4. Memantine
11.4.5. Galantamine
11.4.6. Manufactured Combination of Memantine and Donepezil
11.4.7. Other

12. Global
12.1. Global Alzheimer’s Therapeutic Market, by Drug Class, 2016-2028(US$ Bn)
12.1.1. Overview
12.1.2. Cholinesterase Inhibitors
12.1.3. NMDA Receptor Antagonists
12.1.4. Others
12.2. Global Alzheimer’s Therapeutic Market, by Distribution Channels, 2016-2028(US$ Bn)
12.2.1. Overview
12.2.2. Hospital Pharmacy
12.2.3. Retail Pharmacy
12.2.4. Online Pharmacy
12.2.5. Others
12.3. Global Alzheimer’s Therapeutic Market, by Treatment, 2016-2028(US$ Bn)
12.3.1. Overview
12.3.2. Donepezil
12.3.3. Rivastigmine
12.3.4. Memantine
12.3.5. Galantamine
12.3.6. Manufactured Combination of Memantine and Donepezil
12.3.7. Other

13. Company Profiles
13.1. AbbVie Inc.
13.2. Lannett Inc.
13.3. Teva Pharma Ltd
13.4. Unichem laboratories Ltd
13.5. Eisai Co. Ltd
13.6. Torrent Pharma Ltd
13.7. Janssen Pharma Inc.
13.8. Cipla Ltd
13.9. Novartis AGNovartis AG
13.10. Lupin Ltd
13.11. Zydus Lifesciences Ltd
13.12. Viatris Inc
13.13. Sun Pharma Industries Ltd
13.14. Macleods Pharma Ltd
13.15. Dr. Reddy’s Laboratories Ltd
13.16. Aurobindo Pharma Ltd
13.17. Amneal Pharmaceuticals Inc.
13.18. Others

List of Figures

FIG. 1 Global Alzheimer’s Therapeutic Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Alzheimer’s Therapeutic Market Segmentation
FIG. 4 Global Alzheimer’s Therapeutic Market, by Type, 2019 (US$ Bn)
FIG. 5 Global Alzheimer’s Therapeutic Market, by Drug Class, 2019 (US$ Bn)
FIG. 6 Global Alzheimer’s Therapeutic Market, by Treatment, 2019 (US$ Bn)
FIG. 7 Global Alzheimer’s Therapeutic Market, by Distribution Channels, 2021 (US$ Bn)
FIG. 8 Global Alzheimer’s Therapeutic Market, by Geography, 2021 (US$ Bn)
FIG. 9 Attractive Investment Proposition, by Geography, 2021
FIG. 10 Global Market Positioning of Key Alzheimer’s Therapeutic Market Manufacturers, 2019
FIG. 11 Global Alzheimer’s Therapeutic Market Value Contribution, By Distribution Channels, 2021 & 2028 (Value %)
FIG. 12 Global Alzheimer’s Therapeutic Market, by Hospital Pharmacy, Value, 2016-2028 (US$ Bn)
FIG. 13 Global Alzheimer’s Therapeutic Market, by Retail Pharmacy, Value, 2016-2028 (US$ Bn)
FIG. 14 Global Alzheimer’s Therapeutic Market, by Online Pharmacy, Value, 2016-2028 (US$ Bn)
FIG. 15 Global Alzheimer’s Therapeutic Market Value Contribution, By Drug Class, 2021 & 2028 (Value %)
FIG. 16 Global Alzheimer’s Therapeutic Market, by Cholinesterase Inhibitors, 2016-2028 (US$ Bn)
FIG. 17 Global Alzheimer’s Therapeutic Market, by NMDA Receptor Antagonists, Value, 2016-2028 (US$ Bn)
FIG. 18 Global Alzheimer’s Therapeutic Market, by Others, Value, 2016-2028 (US$ Bn)
FIG. 19 Global Alzheimer’s Therapeutic Market Value Contribution, By Treatment, 2021 & 2028 (Value %)
FIG. 20 Global Alzheimer’s Therapeutic Market, by Donepezil, 2016-2028 (US$ Bn)
FIG. 21 Global Alzheimer’s Therapeutic Market, by Rivastigmine, 2016-2028 (US$ Bn)
FIG. 22 Global Alzheimer’s Therapeutic Market, by Memantine, 2016-2028 (US$ Bn)
FIG. 23 U.S. Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 24 Rest of North America Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 25 U.K. Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 26 Germany Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 27 France Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 28 Italy Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 29 Spain Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 30 Russia Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 31 BENELUX Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 32 Poland Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 33 Austria Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 34 Rest of Europe Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 35 Japan Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 36 China Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 37 India Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 38 South Korea Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 39 Australia Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 40 Southeast Asia Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 41 Rest of Asia Pacific Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 42 Middle East & Africa Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 43 South Africa Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 44 Nigeria Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 45 Egypt Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 46 GCC Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 47 Israel Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 48 Latin America Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 49 Mechanicalzil Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 50 Argentina Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 51 Colombia Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 52 Peru Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)
FIG. 53 Chile Alzheimer’s Therapeutic Market, 2016-2028 (US$ Bn)

List of Tables

TABLE 1 Market Snapshot: Global Alzheimer’s Therapeutic Market
TABLE 2 Global Alzheimer’s Therapeutic Market, by Type, 2016-2028 (US$ Bn)
TABLE 3 Global Alzheimer’s Therapeutic Market, by Distribution Channels, 2016-2028 (US$ Bn)
TABLE 4 Global Alzheimer’s Therapeutic Market, by Drug Class, 2016-2028 (US$ Bn)
TABLE 5 Global Alzheimer’s Therapeutic Market, by Treatment, 2016-2028 (US$ Bn)
TABLE 6 Global Alzheimer’s Therapeutic Market, by Geography, 2016-2028 (US$ Bn)
TABLE 7 North America Alzheimer’s Therapeutic Market, by Type, 2016-2028 (US$ Bn)
TABLE 8 North America Alzheimer’s Therapeutic Market, by Distribution Channels, 2016-2028 (US$ Bn)
TABLE 9 North America Alzheimer’s Therapeutic Market, by Drug Class, 2016-2028 (
TABLE 10 North America Alzheimer’s Therapeutic Market, by Treatment, 2016-2028 (US$ Bn)
TABLE 11 North America Alzheimer’s Therapeutic Market, by Country, 2016-2028 (US$ Bn)
TABLE 12 Europe Alzheimer’s Therapeutic Market, by Type, 2016-2028 (US$ Bn)
TABLE 13 Europe Alzheimer’s Therapeutic Market, by Distribution Channels, 2016-2028 (US$ Bn)
TABLE 14 Europe Alzheimer’s Therapeutic Market, by Drug Class, 2016-2028 (US$ Bn)
TABLE 15 Europe Alzheimer’s Therapeutic Market, by Treatment, 2016-2028 (US$ Bn)
TABLE 16 Europe Alzheimer’s Therapeutic Market, by Country/Region, 2016-2028 (US$ Bn)
TABLE 17 Asia Pacific Alzheimer’s Therapeutic Market, by Type, 2016-2028 (US$ Bn)
TABLE 18 Asia Pacific Alzheimer’s Therapeutic Market, by Distribution Channels, 2016-2028 (US$ Bn)
TABLE 19 Asia Pacific Alzheimer’s Therapeutic Market, by Drug Class, 2016-2028 (US$ Bn)
TABLE 20 Asia Pacific Alzheimer’s Therapeutic Market, by Treatment, 2016-2028 (US$ Bn)
TABLE 21 Asia Pacific Alzheimer’s Therapeutic Market, by Country/Region, 2016-2028 (US$ Bn)
TABLE 22 Latin America Alzheimer’s Therapeutic Market, by Type, 2016-2028 (US$ Bn)
TABLE 23 Latin America Alzheimer’s Therapeutic Market, by Distribution Channels, 2016-2028 (US$ Bn)
TABLE 24 Latin America Alzheimer’s Therapeutic Market, by Drug Class, 2016-2028 (US$ Bn)
TABLE 25 Latin America Alzheimer’s Therapeutic Market, by Treatment, 2016-2028 (US$ Bn)
TABLE 26 Latin America Alzheimer’s Therapeutic Market, by Country/Region, 2016-2028 (US$ Bn)
TABLE 27 Middle East Alzheimer’s Therapeutic Market, by Type, 2016-2028 (US$ Bn)
TABLE 28 Middle East Alzheimer’s Therapeutic Market, by Distribution Channels, 2016-2028 (US$ Bn)
TABLE 29 Middle East Alzheimer’s Therapeutic Market, by Drug Class, 2016-2028 (US$ Bn)
TABLE 30 Middle East Alzheimer’s Therapeutic Market, by Treatment, 2016-2028 (US$ Bn)
TABLE 31 Middle East Alzheimer’s Therapeutic Market, by Country/Region, 2016-2028 (US$ Bn)
TABLE 32 Africa Alzheimer’s Therapeutic Market, by Type, 2016-2028 (US$ Bn)
TABLE 33 Africa Alzheimer’s Therapeutic Market, by Distribution Channels, 2016-2028 (US$ Bn)
TABLE 34 Africa Alzheimer’s Therapeutic Market, by Drug Class, 2016-2028 (US$ Bn)
TABLE 35 Africa Alzheimer’s Therapeutic Market, by Treatment, 2016-2028 (US$ Bn)
TABLE 36 Africa Alzheimer’s Therapeutic Market, by Country/Region, 2016-2028 (US$ Bn)

Frequently Asked Questions

How COVID-19 impacted the global Alzheimer’s Therapeutic market?

Alzheimer’s Therapeutic market also suffered from COVID 19 pandemic. Some research studies for Alzheimer’s disease were put on hold during the pandemic outbreak out of concern for contamination.

Which is the leading market for Alzheimer’s Therapeutic?

North America accounted for the highest share in the global Alzheimer’s Therapeutic market in terms of value as well as volume.

What are the key drivers for the growth of the Alzheimer’s Therapeutic market?

The increased incidence and prevalence of Alzheimer’s disease, expanding public health awareness about the condition, and the development of breakthrough technologies and treatments to extend life expectancy are all driving the market.

Which is the major segment in Alzheimer’s Therapeutic Market by Drug Class?

The cholinesterase inhibitors segment accounts for the biggest revenue share of the Global Alzheimer’s Therapeutics market in 2021 and is likely to dominate the market over the forecast period as they are often used by healthcare professionals to treat symptoms linked with memory, thinking, language, judgment, and other thought processes.

Which is the major segment in Alzheimer’s Therapeutic Market by Distribution Channel?

Online Pharmacies had a major share in the global market in 2021 and are projected to continue their dominance over the forecast period.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –